Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Tandem Diabetes enters new agreements with DexCom » 16:25
11/23/20
11/23
16:25
11/23/20
16:25
TNDM

TNDM

/

+

, DXCM

DexCom

$321.34 /

+5.24 (+1.66%)

On November 20, Tandem…

On November 20, Tandem Diabetes Care (TNDM) entered into a Development Agreement and a Commercialization Agreement with DexCom (DXCM). Previously, the company and DexCom had entered into Development Agreements dated June 4, 2015 that facilitated integration of the company's earlier generation insulin pump products with DexCom's G5 and G6 continuous glucose monitoring devices. The New Agreements allow for the continuation of the company's and DexCom's development and collaboration activities that enable the integration of the company's insulin pump products with DexCom's CGM devices. The New Agreements build upon this collaborative relationship, serving to integrate the company's current and future generation insulin pump products with DexCom's G6 and G7 CGM devices. The New Agreements also establish requirements for future communication between the company's and DexCom's digital health products and formalize other development and commercialization processes that were previously handled through informal means. The Development Agreement became effective upon its execution and will continue in effect for as long as the Commercialization Agreement continues in effect, unless terminated earlier. The Commercialization Agreement became effective upon its execution and has an initial term of five years from the date of first commercial launch of any combined system implementation, unless terminated earlier, and thereafter automatically renews for successive two-year periods unless a party provides advance notice of non-renewal. Both Agreements contain customary representations, warranties, covenants, indemnification obligations, and other terms and conditions. The New Agreements do not modify or amend the terms of the company's existing License Agreement dated July 14, 2016 with TypeZero Technologies, a company acquired in 2018 by DexCom.

ShowHide Related Items >><<
TNDM TNDM
/

+

DXCM DexCom
$321.34 /

+5.24 (+1.66%)

TNDM TNDM
/

+

11/06/20 Piper Sandler
Tandem Diabetes price target raised to $132 from $125 at Piper Sandler
10/16/20 Citi
Citi opens 'positive catalyst watch' on DexCom
08/20/20
Fly Intel: Top five analyst initiationsNewPage
08/20/20 Wells Fargo
Tandem Diabetes initiated with an Overweight at Wells Fargo
DXCM DexCom
$321.34 /

+5.24 (+1.66%)

11/20/20 Piper Sandler
DexCom secured national reimbursement in France, says Piper Sandler
10/28/20 Canaccord
DexCom price target lowered to $475 from $500 at Canaccord
10/28/20 Raymond James
DexCom price target lowered to $438 from $450 at Raymond James
10/28/20 Piper Sandler
CMS proposal on CGMs 'modest positive' for Medtronic, says Piper Sandler
TNDM TNDM
/

+

DXCM DexCom
$321.34 /

+5.24 (+1.66%)

TNDM TNDM
/

+

DXCM DexCom
$321.34 /

+5.24 (+1.66%)

Friday
Recommendations
DexCom secured national reimbursement in France, says Piper Sandler » 11:38
11/20/20
11/20
11:38
11/20/20
11:38
DXCM

DexCom

$324.75 /

-5.91 (-1.79%)

, ABT

Abbott

$111.30 /

+0.145 (+0.13%)

DexCom (DXCM) this…

DexCom (DXCM) this morning announced that it has secured national reimbursement for G6 in France, Piper Sandler analyst Matt O'Brien tells investors in a research note. The news is an "important milestone" for the company's outside the U.S. business as this major European market "had been a tough nut to crack" for several years, says the analyst. He believes having national coverage in place should bolster growth through its French distributor and make DexCom more competitive with Abbott (ABT). O'Brien reiterates an Overweight rating on DexCom with a $465 price target.

ShowHide Related Items >><<
DXCM DexCom
$324.75 /

-5.91 (-1.79%)

ABT Abbott
$111.30 /

+0.145 (+0.13%)

DXCM DexCom
$324.75 /

-5.91 (-1.79%)

10/28/20 Canaccord
DexCom price target lowered to $475 from $500 at Canaccord
10/28/20 Raymond James
DexCom price target lowered to $438 from $450 at Raymond James
10/28/20 Piper Sandler
CMS proposal on CGMs 'modest positive' for Medtronic, says Piper Sandler
10/28/20 Piper Sandler
Piper Sandler says buy DexCom despite disappointing G7 update
ABT Abbott
$111.30 /

+0.145 (+0.13%)

11/17/20 Maxim
Co-Diagnostics price target lowered to $20 from $30 at Maxim
10/22/20 SVB Leerink
Abbott price target raised to $115 from $110 at SVB Leerink
10/22/20 Credit Suisse
Abbott price target lowered to $118 from $136 at Credit Suisse
10/16/20 Citi
Citi opens 'positive catalyst watch' on DexCom
DXCM DexCom
$324.75 /

-5.91 (-1.79%)

ABT Abbott
$111.30 /

+0.145 (+0.13%)

ABT Abbott
$111.30 /

+0.145 (+0.13%)

DXCM DexCom
$324.75 /

-5.91 (-1.79%)

ABT Abbott
$111.30 /

+0.145 (+0.13%)

ABT Abbott
$111.30 /

+0.145 (+0.13%)

Over a week ago
Recommendations
Co-Diagnostics price target lowered to $20 from $30 at Maxim » 08:23
11/17/20
11/17
08:23
11/17/20
08:23
CODX

Co-Diagnostics

$13.55 /

-1.38 (-9.24%)

, ABT

Abbott

$113.71 /

+1.12 (+0.99%)

, PFE

Pfizer

$37.34 /

-1.295 (-3.35%)

, MRNA

Moderna

$97.95 /

+8.65 (+9.69%)

Maxim analyst Jason…

Maxim analyst Jason McCarthy lowered the firm's price target on Co-Diagnostics (CODX) to $20 from $30 but keeps a Buy rating on the shares. The analyst notes that the company's Q3 revenue miss reported yesterday may have been a "proverbial gut punch", with damage to the stock already being done by a competitive antigen rapid test from Abbot (ABT) and positive vaccine news from Pfizer (PFE) and Moderna (MRNA). McCarthy adds however that the "big picture" remains positive for Co-Diagnostics in that COVID testing with PCR is "here to stay", further stating that the company has a revenue base to grow its agro, oncology, and infectious diseases tests .

ShowHide Related Items >><<
PFE Pfizer
$37.34 /

-1.295 (-3.35%)

MRNA Moderna
$97.95 /

+8.65 (+9.69%)

CODX Co-Diagnostics
$13.55 /

-1.38 (-9.24%)

ABT Abbott
$113.71 /

+1.12 (+0.99%)

CODX Co-Diagnostics
$13.55 /

-1.38 (-9.24%)

11/17/20 H.C. Wainwright
Co-Diagnostics price target lowered to $29 from $33 at H.C. Wainwright
05/20/20 Maxim
Co-Diagnostics upgraded to Buy from Hold at Maxim
05/20/20 Maxim
Co-Diagnostics upgraded to Buy from Hold at Maxim
05/18/20 H.C. Wainwright
Co-Diagnostics price target raised to $35 from $20 at H.C. Wainwright
ABT Abbott
$113.71 /

+1.12 (+0.99%)

10/22/20 SVB Leerink
Abbott price target raised to $115 from $110 at SVB Leerink
10/22/20 Credit Suisse
Abbott price target lowered to $118 from $136 at Credit Suisse
10/16/20 Citi
Citi opens 'positive catalyst watch' on DexCom
10/09/20 JPMorgan
Abbott price target raised to $125 from $110 at JPMorgan
PFE Pfizer
$37.34 /

-1.295 (-3.35%)

11/17/20 Roth Capital
Inovio downgraded to Sell at Roth Capital on increased competition
11/16/20 Piper Sandler
Piper boosts Moderna target to $166 after 'impressive' vaccine response
11/16/20 Wedbush
Signature Bank added to Best Ideas List at Wedbush
11/13/20 JPMorgan
Pfizer shares reflect close to best case vaccine scenario, says JPMorgan
MRNA Moderna
$97.95 /

+8.65 (+9.69%)

11/17/20 Redburn
Moderna initiated with a Sell at Redburn
11/17/20 BMO Capital
Moderna downgraded to Market Perform from Outperform at BMO Capital
11/16/20 Chardan
Moderna price target raised to $107 from $93 at Chardan
PFE Pfizer
$37.34 /

-1.295 (-3.35%)

MRNA Moderna
$97.95 /

+8.65 (+9.69%)

CODX Co-Diagnostics
$13.55 /

-1.38 (-9.24%)

ABT Abbott
$113.71 /

+1.12 (+0.99%)

  • 19
    May
  • 12
    Feb
PFE Pfizer
$37.34 /

-1.295 (-3.35%)

MRNA Moderna
$97.95 /

+8.65 (+9.69%)

ABT Abbott
$113.71 /

+1.12 (+0.99%)

PFE Pfizer
$37.34 /

-1.295 (-3.35%)

MRNA Moderna
$97.95 /

+8.65 (+9.69%)

CODX Co-Diagnostics
$13.55 /

-1.38 (-9.24%)

ABT Abbott
$113.71 /

+1.12 (+0.99%)

PFE Pfizer
$37.34 /

-1.295 (-3.35%)

MRNA Moderna
$97.95 /

+8.65 (+9.69%)

CODX Co-Diagnostics
$13.55 /

-1.38 (-9.24%)

ABT Abbott
$113.71 /

+1.12 (+0.99%)

Hot Stocks
Abbott launches IonicRF Generator » 09:02
11/10/20
11/10
09:02
11/10/20
09:02
ABT

Abbott

$109.36 /

-5.06 (-4.42%)

Abbott announced the…

Abbott announced the launch of the IonicRF Generator - a new device recently cleared by the FDA to deliver a non-surgical, minimally invasive treatment for the management of pain in the nervous system. The IonicRF Generator is a radiofrequency ablation device that uses heat to target specific nerves and block pain signals from reaching the brain. The new device is the first Abbott-developed radiofrequency ablation device and is currently approved in the United States and Europe. Radiofrequency ablation uses an electric current to heat up a small area of nerve tissue to stop it from sending pain signals.

ShowHide Related Items >><<
ABT Abbott
$109.36 /

-5.06 (-4.42%)

ABT Abbott
$109.36 /

-5.06 (-4.42%)

10/22/20 SVB Leerink
Abbott price target raised to $115 from $110 at SVB Leerink
10/22/20 Credit Suisse
Abbott price target lowered to $118 from $136 at Credit Suisse
10/16/20 Citi
Citi opens 'positive catalyst watch' on DexCom
10/09/20 JPMorgan
Abbott price target raised to $125 from $110 at JPMorgan
ABT Abbott
$109.36 /

-5.06 (-4.42%)

ABT Abbott
$109.36 /

-5.06 (-4.42%)

ABT Abbott
$109.36 /

-5.06 (-4.42%)

ABT Abbott
$109.36 /

-5.06 (-4.42%)

Recommendations
DexCom price target lowered to $475 from $500 at Canaccord » 09:27
10/28/20
10/28
09:27
10/28/20
09:27
DXCM

DexCom

$380.38 /

-37.52 (-8.98%)

Canaccord analyst Kyle…

Canaccord analyst Kyle Rose lowered the firm's price target on DexCom to $475 from $500 and keeps a Buy rating on the shares. The analyst said he sees a lot of positivity in the results but with the shares up so much year-to-date, he expects them to continue to consolidate over the next few days until after the election. Given its pipeline, growing TAM, and operating metrics, he sees no reason not to remain bullish in the near-term.

ShowHide Related Items >><<
DXCM DexCom
$380.38 /

-37.52 (-8.98%)

DXCM DexCom
$380.38 /

-37.52 (-8.98%)

10/28/20 Raymond James
DexCom price target lowered to $438 from $450 at Raymond James
10/28/20 Piper Sandler
CMS proposal on CGMs 'modest positive' for Medtronic, says Piper Sandler
10/28/20 Piper Sandler
Piper Sandler says buy DexCom despite disappointing G7 update
10/27/20 Canaccord
DexCom weakness a buying opportunity, says Canaccord
DXCM DexCom
$380.38 /

-37.52 (-8.98%)

DXCM DexCom
$380.38 /

-37.52 (-8.98%)

DXCM DexCom
$380.38 /

-37.52 (-8.98%)

Recommendations
DexCom price target lowered to $438 from $450 at Raymond James » 09:00
10/28/20
10/28
09:00
10/28/20
09:00
DXCM

DexCom

$380.38 /

-37.52 (-8.98%)

Raymond James analyst…

Raymond James analyst Jayson Bedford lowered the firm's price target on DexCom to $438 from $450 and keeps an Outperform rating on the shares. Bedford says Q3 profitability was better than expected and addresses the pricing pressure-related margins concerns, and calls the commentary around G7 COGS "encouraging."

ShowHide Related Items >><<
DXCM DexCom
$380.38 /

-37.52 (-8.98%)

DXCM DexCom
$380.38 /

-37.52 (-8.98%)

10/28/20 Piper Sandler
CMS proposal on CGMs 'modest positive' for Medtronic, says Piper Sandler
10/28/20 Piper Sandler
Piper Sandler says buy DexCom despite disappointing G7 update
10/27/20 Canaccord
DexCom weakness a buying opportunity, says Canaccord
10/27/20 Baird
DexCom weakness a buying opportunity, says Baird
DXCM DexCom
$380.38 /

-37.52 (-8.98%)

DXCM DexCom
$380.38 /

-37.52 (-8.98%)

DXCM DexCom
$380.38 /

-37.52 (-8.98%)

Recommendations
CMS proposal on CGMs 'modest positive' for Medtronic, says Piper Sandler » 05:42
10/28/20
10/28
05:42
10/28/20
05:42
MDT

Medtronic

$105.18 /

-2.72 (-2.52%)

, DXCM

DexCom

$380.38 /

-37.52 (-8.98%)

Centers for Medicare and…

Centers for Medicare and Medicaid Services announced last night a set of continuous glucose monitoring proposals for the durable medical equipment channel, Piper Sandler analyst Matt O'Brien tells investors in a research note. The proposal would allow adjunctive CGMs to receive Medicare coverage, which was not the policy prior, says the analyst. O'Brien believes the disclosure would benefit Medtronic, which he does not have CGM coverage in the Medicare population as its Guardian Sensor 3 is an adjunctive sensor. This proposal would allow Medtronic to enter the Medicare population with its current sensor, the analyst points out. O'Brien views the CMS disclosure as a "modest positive" for Medtronic, adding the company "remains behind technologically." Further, he doubts that DexCom (DXCM) will be adversely affected by this announcement.

ShowHide Related Items >><<
MDT Medtronic
$105.18 /

-2.72 (-2.52%)

DXCM DexCom
$380.38 /

-37.52 (-8.98%)

MDT Medtronic
$105.18 /

-2.72 (-2.52%)

10/16/20 Morgan Stanley
Morgan Stanley positively biased on Medtronic, but awaits execution
10/16/20 Citi
Citi opens 'positive catalyst watch' on DexCom
10/15/20 Cowen
Medtronic moving closer to med-tech growth leaders, says Cowen
10/14/20 Piper Sandler
Medtronic raises revenue growth outlook to 5% from 4%, says Piper Sandler
DXCM DexCom
$380.38 /

-37.52 (-8.98%)

10/28/20 Piper Sandler
Piper Sandler says buy DexCom despite disappointing G7 update
10/27/20 Canaccord
DexCom weakness a buying opportunity, says Canaccord
10/27/20 Baird
DexCom weakness a buying opportunity, says Baird
10/26/20 Piper Sandler
DexCom's Q3 pre-announcement impacted by tough comp, says Piper Sandler
MDT Medtronic
$105.18 /

-2.72 (-2.52%)

DXCM DexCom
$380.38 /

-37.52 (-8.98%)

MDT Medtronic
$105.18 /

-2.72 (-2.52%)

DXCM DexCom
$380.38 /

-37.52 (-8.98%)

MDT Medtronic
$105.18 /

-2.72 (-2.52%)

DXCM DexCom
$380.38 /

-37.52 (-8.98%)

MDT Medtronic
$105.18 /

-2.72 (-2.52%)

Recommendations
Piper Sandler says buy DexCom despite disappointing G7 update » 05:11
10/28/20
10/28
05:11
10/28/20
05:11
DXCM

DexCom

$380.38 /

-37.52 (-8.98%)

DexCom's Q3 revenue…

DexCom's Q3 revenue was above Street estimates and total volume growth was about 40% year-over-year with pricing under more pressure than expected, Piper Sandler analyst Matt O'Brien tells investors in a research note. Further, the company's fiscal 2020 guidance "ticked up nicely on all fronts, which was a positive development," adds the analyst. O'Brien says the biggest update was G7. The good news is that a version will hit several key markets during the second half of 2021, but will only be a 10 day sensor rather than 15, O'Brien notes. He says that while the update is likely to be disappointing, he recommends purchase of DexCom shares with an Overweight rating and $465 price target.

ShowHide Related Items >><<
DXCM DexCom
$380.38 /

-37.52 (-8.98%)

DXCM DexCom
$380.38 /

-37.52 (-8.98%)

10/27/20 Canaccord
DexCom weakness a buying opportunity, says Canaccord
10/27/20 Baird
DexCom weakness a buying opportunity, says Baird
10/26/20 Piper Sandler
DexCom's Q3 pre-announcement impacted by tough comp, says Piper Sandler
10/16/20 Citi
Citi opens 'positive catalyst watch' on DexCom
DXCM DexCom
$380.38 /

-37.52 (-8.98%)

DXCM DexCom
$380.38 /

-37.52 (-8.98%)

DXCM DexCom
$380.38 /

-37.52 (-8.98%)

Earnings
Dexcom raises FY20 revenue view to roughly $1.9B from $1.85B, consensus $1.87B » 16:06
10/27/20
10/27
16:06
10/27/20
16:06
DXCM

DexCom

$382.70 /

-35.2 (-8.42%)

Raises FY20 adjusted…

Raises FY20 adjusted EBITDA margin view to meeting or exceeding 26% from 24%.

ShowHide Related Items >><<
DXCM DexCom
$382.70 /

-35.2 (-8.42%)

DXCM DexCom
$382.70 /

-35.2 (-8.42%)

10/27/20 Canaccord
DexCom weakness a buying opportunity, says Canaccord
10/27/20 Baird
DexCom weakness a buying opportunity, says Baird
10/26/20 Piper Sandler
DexCom's Q3 pre-announcement impacted by tough comp, says Piper Sandler
10/16/20 Citi
Citi opens 'positive catalyst watch' on DexCom
DXCM DexCom
$382.70 /

-35.2 (-8.42%)

DXCM DexCom
$382.70 /

-35.2 (-8.42%)

DXCM DexCom
$382.70 /

-35.2 (-8.42%)

Earnings
Dexcom reports Q3 adjusted EPS 94c, consensus 64c » 16:05
10/27/20
10/27
16:05
10/27/20
16:05
DXCM

DexCom

$382.80 /

-35.1 (-8.40%)

Reports Q3 revenue…

Reports Q3 revenue $500.9M, consensus $476.75M. "The third quarter was another strong period of growth for Dexcom as awareness of our technology continues to grow in this time of heightened focus on glycemic health," said Kevin Sayer, Dexcom's chairman, president and CEO. "We are once again pleased to raise our full-year 2020 guidance as our teams press forward to close the year strong and execute on our strategic initiatives."

ShowHide Related Items >><<
DXCM DexCom
$382.80 /

-35.1 (-8.40%)

DXCM DexCom
$382.80 /

-35.1 (-8.40%)

10/27/20 Canaccord
DexCom weakness a buying opportunity, says Canaccord
10/27/20 Baird
DexCom weakness a buying opportunity, says Baird
10/26/20 Piper Sandler
DexCom's Q3 pre-announcement impacted by tough comp, says Piper Sandler
10/16/20 Citi
Citi opens 'positive catalyst watch' on DexCom
DXCM DexCom
$382.80 /

-35.1 (-8.40%)

DXCM DexCom
$382.80 /

-35.1 (-8.40%)

DXCM DexCom
$382.80 /

-35.1 (-8.40%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.